A recent press release from Mount Sinai Health System announced the FDA approval of mirikizumab, a novel treatment for moderate-to-severe ulcerative colitis (UC). As the first antibody targeting p19/interleukin-23, it effectively manages crucial symptoms like bowel urgency, improving patient quality of life. Clinical trials demonstrated mirikizumab’s efficacy in both inducing and maintaining remission in patients with UC, and its favorable safety profile and ability to maintain long-term remission make it a valuable new treatment option for UC.
Reference: Mount Sinai Health System. FDA Approves Mirikizumab, a Promising Induction and Maintenance Therapy for Ulcerative Colitis. Mount Sinai. Published October 27, 2023. Accessed December 15, 2023. https://www.mountsinai.org/about/newsroom/2023/fda-approves-mirikizumab-a-promising-induction-and-maintenance-therapy-for-ulcerative-colitis
